Beyond structure: Defining the function of the gut using omic approaches for rational design of personalized therapeutics

mSystems

Volumn 3, Issue 2, 2018, Pages

  Theriot, Casey M ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Bile acids; Clostridium difficile; Metabolome; Microbiota; Obesity; Therapeutics

Indexed keywords

MICROBIAL ENZYME;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; FUTUROLOGY; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE; INTESTINE FLORA; METABOLIC DISORDER; NONHUMAN; OMICS; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

EID: 85045220797     PISSN: None     EISSN: 23795077     Source Type: Journal    
DOI: 10.1128/mSystems.00173-17     Document Type: Article

References (15)

1. Theriot CM, Du X, Tove SR, Grunden AM. 2010. Improving the catalytic activity of hyperthermophilic Pyrococcus prolidases for detoxification of organophosphorus nerve agents over a broad range of temperatures. Appl Microbiol Biotechnol 87:1715–1726. https://doi.org/10.1007/s00253-010-2614-3.
2. Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, Huffnagle GB, Z Li J, Young VB. 2014. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5:3114. https://doi.org/10.1038/ncomms4114.
3. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372: 825–834. https://doi.org/10.1056/NEJMoa1408913.
4. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. 2016. Clostridium difficile infection. Nat Rev Dis Prim 2:16020. https://doi.org/10.1038/nrdp.2016.20.
5. Theriot CM, Young VB. 2015. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol 69:445–461. https://doi.org/10.1146/annurev-micro-091014-104115.
6. Jansson JK, Baker ES. 2016. A multi-omic future for microbiome studies. Nat Microbiol 1:16049. https://doi.org/10.1038/nmicrobiol.2016.49.
7. Winston JA, Thanissery R, Montgomery SA, Theriot CM. 2016. Cefoperazone-treated mouse model of clinically relevant Clostridium difficile strain R20291. J Vis Exp https://doi.org/10.3791/54850.
8. Russell DW. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137–174. https://doi.org/10.1146/annurev.biochem.72.121801.161712.
9. Ridlon JM, Kang DJ, Hylemon PB. 2006. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259. https://doi.org/10.1194/jlr.R500013-JLR200.
10. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, Hill C, Gahan CG. 2014. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A 111:7421–7426. https://doi.org/10.1073/pnas.1323599111.
11. van Pijkeren JP, Barrangou R. 2017. Genome editing of food-grade lactobacilli to develop therapeutic probiotics. Microbiol Spectr 5:5. https://doi.org/10.1128/microbiolspec.BAD-0013-2016.
12. Noecker C, Eng A, Srinivasan S, Theriot CM, Young VB, Jansson JK, Fredricks DN, Borenstein E. 2016. Metabolic model-based integration of microbiome taxonomic and metabolomic profiles elucidates mechanistic links between ecological and metabolic variation. mSystems 1:1. https://doi.org/10.1128/mSystems.00013-15.
13. Pollet RM, D’Agostino EH, Walton WG, Xu Y, Little MS, Biernat KA, Pellock SJ, Patterson LM, Creekmore BC, Isenberg HN, Bahethi RR, Bhatt AP, Liu J, Gharaibeh RZ, Redinbo MR. 2017. An atlas of beta-glucuronidases in the human intestinal microbiome. Structure 25:967–977.e5. https://doi.org/10.1016/j.str.2017.05.003.
14. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto S, Terrapon N, Muller A, Young VB, Henrissat B, Wilmes P, Stappenbeck TS, Núñez G, Martens EC. 2016. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167:1339 –1353.e21. https://doi.org/10.1016/j.cell.2016.10.043.
15. Kirk JA, Gebhart D, Buckley AM, Lok S, Scholl D, Douce GR, Govoni GR, Fagan RP. 2017. New class of precision antimicrobials redefines role of Clostridium difficile S-layer in virulence and viability. Sci Transl Med 9:eaah6813. https://doi.org/10.1126/scitranslmed.aah6813.